Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Disitamab vedotin - Yantai Rongchang Pharmaceutical

X
Drug Profile

Disitamab vedotin - Yantai Rongchang Pharmaceutical

Alternative Names: Aidixi; RC 48; RC 48-ADC; Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate - Yantai Rongchang Pharmaceutical

Latest Information Update: 03 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yantai Rongchang Biological Engineering
  • Developer RemeGen; Seagen
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Registered Urogenital cancer
  • Phase III HER2 positive breast cancer
  • Phase II Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Gynaecological cancer; Malignant melanoma; Solid tumours
  • Phase I/II Non-small cell lung cancer
  • Phase I Prostate cancer

Most Recent Events

  • 30 Apr 2024 RemeGen Co plans a phase II trial for Breast cancer (Combination therapy, First-line therapy, Neoadjuvant therapy) in China (IV, Infusion), in April 2024 (NCT06389006)
  • 29 Apr 2024 Phase-II clinical trials in Breast cancer (Neoadjuvant therapy, Combination therapy) in China (IV) (NCT06389006)
  • 23 Apr 2024 RemeGen plans phase I/II trial in Bladder cancer in China (NCT06378242)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top